Sengul C. Ozdek, Sibel Eryigit, Berati Hasanreisoglu (Ankara, Turkey)


To document the incidence of RPE tears after anti-VEGF therapy.


The reports of patients with wet ARMD treated with anti-VEGFs were reviewed for occurrence of RPE tears. Lesion type, the type of anti-VEGF used and prognosis after RPE tear were analyzed.


A total of 538 eyes of 497 patients were reviewed. Total number of injections was 1314 (35% Ranibizumab, 64% Bevacizumab). RPE tear occurred in 15 eyes (1.14%); 10 were associated with Bevacizumab (10/852 eyes, %1.17) and 5 with Ranibizumab (5/462 eyes 1.08%). The difference was not statistically significant. Lesion type was fibrovascular PED in all. The mean VA was 0.89 logMAR at the beginning, 0.93 logMAR at the last visit. The mean follow-up was 10 months.


RPE tear may occur in 1.1% of wet ARMD lesions involving fibrovascular PED during anti-VEGF treatment.